Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia

Clinical and Experimental Immunology

Volumn 170, Issue 3, 2012, Pages 321-332

  Litzman, J ^a   Nechvatalova, J ^a   Xu, J ^b   Ticha, O ^a   Vlkova, M ^a   Hel, Z ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b University of Alabama at Birmingham   (United States)

Author keywords

Common variable immunodeficiency; Endotoxin; IgA deficiency; Lymphocyte activation

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; IMMUNOGLOBULIN A; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOPOLYSACCHARIDE;

ADULT; AGED; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; ENDOTOXEMIA; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN A DEFICIENCY; LIVER FUNCTION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD14; B-LYMPHOCYTES; BRONCHIECTASIS; C-REACTIVE PROTEIN; COMMON VARIABLE IMMUNODEFICIENCY; ENDOTOXEMIA; FEMALE; GRANULOMA; HUMANS; IGA DEFICIENCY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIPOPOLYSACCHARIDES; LIVER DISEASES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SPLENOMEGALY; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84868248885     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04655.x     Document Type: Article

References (74)

1. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145:709-727.
2. Latiff AH, Kerr MA. The clinical significance of immunoglobulin A deficiency. Ann Clin Biochem 2007; 44:131-139.
3. Hammarström L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol 2000; 120:225-231.
4. Guazzi V, Aiuti F, Mezzaroma I etal. Assessment of thymic output in common variable immunodeficiency patients by evaluation of T cell receptor excision circles. Clin Exp Immunol 2002; 129:346-353.
5. Vlková M, Thon V, Sárfyová M etal. Age dependency and mutual relations in T and B lymphocyte abnormalities in common variable immunodeficiency patients. Clin Exp Immunol 2006; 143:373-379.
6. Litzman J, Vlkova M, Pikulova Z, Stikarovska D, Lokaj J. T and B lymphocyte subpopulations and activation/differentiation markers in patients with selective IgA deficiency. Clin Exp Immunol 2007; 147:249-254.
7. Aspalter RM, Sewell WA, Dolman K, Farrant J, Webster AD. Deficiency in circulating natural killer (NK) cell subsets in common variable immunodeficiency and X-linked agammaglobulinaemia. Clin Exp Immunol 2000; 121:506-514.
8. Nechvatalova J, Pikulova Z, Stikarovska D, Pesak S, Vlkova M, Litzman J. B-lymphocyte subpopulations in patients with selective IgA deficiency. J Clin Immunol 2012; 32:441-448.
9. Marashi SM, Raeiszadeh M, Workman S etal. Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus. J Allergy Clin Immunol 2011; 127:1385-1393.
10. Jirillo E, Caccavo D, Magrone T etal. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 2002; 8:319-327.
11. Urbaschek R, McCuskey RS, Rudi V etal. Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol Clin Exp Res 2001; 25:261-268.
12. Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 1987; 4:8-14.
13. Harte AL, da Silva NF, Creely SJ etal. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010; 7:15.
14. Sandler NG, Koh C, Roque A etal. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220-1230.
15. Pastor Rojo O, López San Román A, Albéniz Arbizu E, de la Hera Martínez A, Ripoll Sevillano E, Albillos Martínez A. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:269-277.
16. Estes JD, Harris LD, Klatt NR etal. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog 2010; 6:e1001052.
17. Kotler DP. HIV infection and the gastrointestinal tract. AIDS 2005; 19:107-117.
18. Sharpstone D, Neild P, Crane R etal. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut 1999; 45:70-76.
19. George MD, Reay E, Sankaran S, Dandekar S. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 2005; 79:2709-2719.
20. Brenchley JM, Price DA, Schacker TW etal. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
21. Sandler NG, Wand H, Roque A etal. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-790.
22. Balagopal A, Philp FH, Astemborski J etal. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135:226-233.
23. Hel Z, McGhee JR, Mestecky J. HIV infection: first battle decides the war. Trends Immunol 2006; 27:274-281.
24. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005; 11:225-229.
25. Verhasselt V, Buelens C, Willems F, De Groote D, Haeffner-Cavaillon N, Goldman M. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J Immunol 1997; 158:2919-2925.
26. Gioannini TL, Weiss JP. Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells. Immunol Res 2007; 39:249-260.
27. Miyake K. Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotoxin Res 2006; 12:195-204.
28. Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol 1991; 147:1567-1574.
29. Hiki N, Berger D, Prigl C etal. Endotoxin binding and elimination by monocytes: secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria. Infect Immun 1998; 66:1135-1141.
30. Landmann R, Knopf HP, Link S, Sansano S, Schumann R, Zimmerli W. Human monocyte CD14 is upregulated by lipopolysaccharide. Infect Immun 1996; 64:1762-1769.
31. Cross AS, Opal SM, Warren HS etal. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J Infect Dis 2001; 183:1079-1086.
32. Kitchens RL, Thompson PA, Viriyakosol S, O'Keefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001; 108:485-493.
33. Ketchum PA, Novitsky TJ. Assay of endotoxin by limulus amebocyte lysate. Methods Mol Med 2000; 36:3-12.
34. Eichbaum EB, Harris HW, Kane JP, Rapp JH. Chylomicrons can inhibit endotoxin activity in vitro. J Surg Res 1991; 51:413-416.
35. Sohn EJ, Paape MJ, Bannerman DD, Connor EE, Fetterer RH, Peters RR. Shedding of sCD14 by bovine neutrophils following activation with bacterial lipopolysaccharide results in down-regulation of IL-8. Vet Res 2007; 38:95-108.
36. Rodeberg DA, Morris RE, Babcock GF. Azurophilic granules of human neutrophils contain CD14. Infect Immun 1997; 65:4747-4753.
37. Detmers PA, Zhou D, Powell D, Lichenstein H, Kelley M, Pironkova R. Endotoxin receptors (CD14) are found with CD16 (Fc gamma RIII) in an intracellular compartment of neutrophils that contains alkaline phosphatase. J Immunol 1995; 155:2085-2095.
38. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 is an acute-phase protein. J Immunol 2004; 172:4470-4479.
39. Liu S, Khemlani LS, Shapiro RA etal. Expression of CD14 by hepatocytes: upregulation by cytokines during endotoxemia. Infect Immun 1998; 66:5089-5098.
40. Su GL, Dorko K, Strom SC, Nussler AK, Wang SC. CD14 expression and production by human hepatocytes. J Hepatol 1999; 31:435-442.
41. Pan Z, Zhou L, Hetherington CJ, Zhang DE. Hepatocytes contribute to soluble CD14 production, and CD14 expression is differentially regulated in hepatocytes and monocytes. J Biol Chem 2000; 275:36430-36435.
42. Egerer K, Feist E, Rohr U, Pruss A, Burmester GR, Dorner T. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000; 9:614-621.
43. Takeshita S, Nakatani K, Tsujimoto H, Kawamura Y, Kawase H, Sekine I. Increased levels of circulating soluble CD14 in Kawasaki disease. Clin Exp Immunol 2000; 119:376-381.
44. Nockher WA, Wigand R, Schoeppe W, Scherberich JE. Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin Exp Immunol 1994; 96:15-19.
45. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190-197.
46. Wehr C, Kivioja T, Schmitt C etal. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111:77-85.
47. Malphettes M, Gérard L, Carmagnat M etal. Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis 2009; 49:1329-1338.
48. Lakatos PL, Kiss LS, Palatka K etal. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2011; 17:767-777.
49. Afdhal N, McHutchison J, Brown R etal. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008; 48:1000-1007.
50. Greenberg SJ, Marcon L, Hurwitz BJ, Waldmann TA, Nelson DL. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Engl J Med 1988; 319:1019-1020.
51. Makis AC, Galanakis E, Hatzimichael EC, Papadopoulou ZL, Siamopoulou A, Bourantas KL. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis. J Infect 2005; 51:206-210.
52. Giordano C, Galluzzo A, Marco A etal. Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. Diabetes Res 1988; 8:135-138.
53. Agarwal S, Smereka P, Harpaz N, Cunningham-Rundles C, Mayer L. Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease. Inflamm Bowel Dis 2011; 17:251-259.
54. Kalha I, Sellin JH. Common variable immunodeficiency and the gastrointestinal tract. Curr Gastroenterol Rep 2004; 6:377-383.
55. Agarwal S, Mayer L. Gastrointestinal manifestations in primary immune disorders. Inflamm Bowel Dis 2010; 16:703-711.
56. Miki K, Moore DJ, Butler RN, Southcott E, Couper RT, Davidson GP. The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease. J Pediatr 1998; 133:750-754.
57. Arias MA, Rey Nores JE, Vita N etal. Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. J Immunol 2000; 164:3480-3486.
58. Almeida J, Galhenage S, Yu J, Kurtovic J, Riordan SM. Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol 2006; 12:1493-1502.
59. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18:353-372.
60. Ward C, Lucas M, Piris J, Collier J, Chapel H. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol 2008; 153:331-337.
61. Malamut G, Ziol M, Suarez F etal. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol 2008; 48:74-82.
62. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-454.
63. Meuleman P, Steyaert S, Libbrecht L etal. Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection. Clin Chim Acta 2006; 366:156-162.
64. Matsuura K, Ishida T, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S. Upregulation of mouse CD14 expression in Kupffer cells by lipopolysaccharide. J Exp Med 1994; 179:1671-1676.
65. Tomita M, Yamamoto K, Kobashi H, Ohmoto M, Tsuji T. Immunohistochemical phenotyping of liver macrophages in normal and diseased human liver. Hepatology 1994; 20:317-325.
66. Sandler NG, Koh C, Roque A etal. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220-1230 e3.
67. Witkowska AM. On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm 2005; 2005:121-130.
68. North ME, Spickett GP, Webster AD, Farrant J. Raised serum levels of CD8, CD25 and beta 2-microglobulin in common variable immunodeficiency. Clin Exp Immunol 1991; 86:252-255.
69. Bank U, Reinhold D, Schneemilch C, Kunz D, Synowitz HJ, Ansorge S. Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation. J Interferon Cytokine Res 1999; 19:1277-1287.
70. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RHA. novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001; 61:237-242.
71. Warnatz K, Schlesier M. Flowcytometric phenotyping of common variable immunodeficiency. Cytometry B Clin Cytom 2008; 74:261-271.
72. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21:265-304.
73. Atkinson K, Hansen JA, Storb R, Goehle S, Goldstein G, Thomas ED. T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets. Blood 1982; 59:1292-1298.
74. Watanabe N, De Rosa SC, Cmelak A, Hoppe R, Herzenberg LA, Roederer M. Long-term depletion of naive T cells in patients treated for Hodgkin's disease. Blood 1997; 90:3662-3672.